Sarepta Faces Safety Concerns and Restructuring Amid Patient Deaths
TL;DR Summary
Sarepta Therapeutics reported a third patient death due to acute liver failure after receiving its gene therapy, adding to recent fatalities of two teenage boys, which has led to stock decline and increased regulatory scrutiny, including a warning label from the FDA.
- Sarepta Says Another Patient Died After Receiving Gene Therapy Bloomberg.com
- Patient dies in Sarepta gene therapy trial, adding to safety concerns STAT
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Sarepta Therapeutics
- Third death from a Sarepta gene therapy BioCentury
- Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting The Boston Globe
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
87%
321 → 42 words
Want the full story? Read the original article
Read on Bloomberg.com